Biocept Inc (NASDAQ:BIOC) announced the appointments of Samuel Riccitelli as the company’s new interim CEO as well as Antonino Morales as its interim chief financial officer (CFO).
Biocept also said it named M. Faye Wilson as its lead independent director, while Riccitelli will remain chairman of the company’s board of directors.
“I am grateful and excited to see Sam and Antonino stepping into their interim roles at a time when Biocept is fulfilling such an important mission for our current COVID-19 testing clients and I am even more excited about what their leadership will mean to malignant tumor patients as we pursue the clinical validation of the CNSide assay in identifying metastatic cancer originating from all solid tumors,” Wilson said in a statement.
READ: Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
Riccitelli, who has worked in the healthcare industry for more than 35 years, has served as a member of Biocept’s board of directors since October 2020, while Morales has sat on Biocept’s board since July 2021 and has more than 30 years of broad leadership experience in the US and Latin America.
Biocept develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment, and monitoring of patients with cancer.
The company is also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during the pandemic.
Contact Sean at sean@proactiveinvestors.com